ATMP Development In 2025: Promise, Pressure, And The Push To Scale

As the advanced therapy medicinal products (ATMP) sector moves through the midpoint of 2025, the pace of innovation shows no signs of slowing. Breakthrough CRISPR-based treatments continue to capture headlines, patient access to cell and gene therapies is expanding beyond early adopter regions, and a steadily evolving global regulatory framework is opening new pathways for commercialization. Yet, with this promise also comes mounting pressure.

In a recent episode of Beyond Biotech, the podcast by Labiotech, Alison Pritchard, Vice President of Business Development for EMEA at Cryoport Systems, shared an honest perspective on the state of the industry and the hurdles that must be overcome to successfully scale the next generation of therapies.

“2025 so far is really highlighting the therapeutic impact and the promise of cell and gene therapies,” Alison noted. “We’re seeing more patients than ever actually gaining access to these treatments.”

This shift is both significant and encouraging. However, as Alison emphasized, progress has not come without its challenges. Developers are navigating a tighter funding climate, persistent supply chain and operational inefficiencies, and the constant demand to accelerate development timelines. The reality is that companies are being asked to achieve more, in less time, and with fewer resources, while minimizing errors that could compromise patient access or delay critical advancements.